SABS compared with ANTX: revenue, margins and what each company keeps, and the suppliers and customers both name

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

ANTXAN2 Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SABSSAB Biotherapeutics, Inc.

ANTXAN2 Therapeutics, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

SABS

No earnings history for SABS.

ANTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±60.5%▲+6.98%×0.12

= impliedSABS realized, solidANTX realized, hatchedOne scale, both sides: full bar = 61%× = |realized| ÷ impliedSource: market data

SABSSAB Biotherapeutics, Inc.

3.02▲+2.59%· post 3.02

Mkt cap$273.0MRevenue$114,698Q4 FY24

ANTXAN2 Therapeutics, Inc.

4.00▲+1.14%· post 4.00

ClosedNov 6 '26

Mkt cap$150.9MRevenue—

Compare

ClosedNov 6 '26

SABSSAB Biotherapeutics, Inc.

ANTXAN2 Therapeutics, Inc.

3.02▲+2.59%post 3.02

Price

4.00▲+1.14%post 4.00

$273.0M

Mkt cap

$150.9M

Q4 FY24$114,698

Revenue

—

SABS3.02▲+2.59%vsANTX4.00▲+1.14%ClosedNov 6 '26